
    
      Cohort 1 will consist of 10 subjects dosed at 400 mcg/d. Cohort 2 will consist of 10 subjects
      dosed at 600 mcg/d. All doses will be given as a 28-day continuous IV infusion, followed by a
      2 week treatment-free interval, until subject experiences disease progression as per
      International Myeloma Working Group (IMWG) criteria.
    
  